Combining A452 (an HDAC6 selective inhibitor) with either lenalidomide or pomalidomide (immunomodulatory drugs (IMiDs)) synergistically increased the apoptosis in multiple myeloma cells by inactivating AKT and extracellular signal-regulated kinase (ERK)1/2 [99]. The gene discussed is HDAC6; the disease is plasma cell myeloma.